SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
风中盼易
Lv0
4
0 积分
2024-08-22 加入
最近求助
最近应助
互助留言
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
1小时前
已完结
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme)
1小时前
已关闭
Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme
1小时前
已关闭
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
1小时前
已完结
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis
1小时前
已完结
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program
2小时前
已完结
Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity
2小时前
已完结
Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity
2小时前
已完结
Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials
2小时前
求助中
Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo
2小时前
已关闭
没有进行任何应助
找到了【积分已退回】
1小时前
找到了【积分已退回】
1小时前
找到了【积分已退回】
2小时前
帮大忙了,速度真快,点赞
1天前
感谢,点赞,速度真快,帮大忙了,么么哒
1天前
帮大忙了
23天前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论